BCD-256 vs Litifilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Systemic Lupus Erythematosus

Shared mechanism: BDCA2 (CLEC4C) · full Systemic Lupus Erythematosus pipeline

BCD-256

Developed by Biocad

Phase 1 in Systemic Lupus Erythematosusmonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Litifilimab

Developed by Biogen

Phase 3 in Systemic Lupus Erythematosusmonoclonal antibody
Reliable signal

NCT02847598 · Phase 2 · completed

This was a randomized, double-blind (participant and investigator), placebo-controlled trial with 264 enrolled participants and hard clinical primary endpoints (28-joint active joint count and CLASI-A skin activity score). The primary comparisons reached statistical significance in the favorable direction: Part A 450 mg vs placebo active-joint LS mean difference -3.4 (95% CI -6.7 to -0.2, p=0.037), and Part B CLASI-A LS mean differences -24.29 to -33.42 (p=0.015 to <0.001 across doses).

Next expected readout: May 2032 · NCT05352919 (registry estimate)

Reported efficacy

Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24); Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 (Baseline to Week 16): Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) (met)

Result source: NCT02847598

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCD-256Litifilimab
SRI-4—Not reported56.3% vs 28.6%+27.7 vs placebo450 mg · wk 24 · n 64NCT02847598
2 other results
  • 16.7% vs 28.6% 150 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
  • 33.3% vs 28.6% 50 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
BICLA—Not reported—Trial running · NCT04961567
CLASI-50—Not reported64.1% vs 42.1%+22 vs placebo450 mg · wk 24 · n 39NCT02847598
8 other results
  • 46.5% vs 21.9% 450 mg · wk 16 · n 48 · Phase 2 · secondary NCT02847598
  • 37.5% vs 12.1% 450 mg · wk 12 · n 48 · Phase 2 · secondary NCT02847598
  • 44% vs 21.9% 150 mg · wk 16 · n 25 · Phase 2 · secondary NCT02847598
  • 48% vs 12.1% 150 mg · wk 12 · n 25 · Phase 2 · secondary NCT02847598
  • 38.5% vs 21.9% 50 mg · wk 16 · n 26 · Phase 2 · secondary NCT02847598
  • 38.5% vs 12.1% 50 mg · wk 12 · n 26 · Phase 2 · secondary NCT02847598
  • 16.7% vs 42.1% 150 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
  • 50% vs 42.1% 50 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
Steroid sparing—Not reported—Trial running · NCT04961567

SRI-4

BCD-256
—Not reported
Litifilimab
56.3% vs 28.6%+27.7 vs placebo450 mg · wk 24 · n 64NCT02847598
2 other results
  • 16.7% vs 28.6% 150 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
  • 33.3% vs 28.6% 50 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598

BICLA

BCD-256
—Not reported
Litifilimab
—Trial running · NCT04961567

CLASI-50

BCD-256
—Not reported
Litifilimab
64.1% vs 42.1%+22 vs placebo450 mg · wk 24 · n 39NCT02847598
8 other results
  • 46.5% vs 21.9% 450 mg · wk 16 · n 48 · Phase 2 · secondary NCT02847598
  • 37.5% vs 12.1% 450 mg · wk 12 · n 48 · Phase 2 · secondary NCT02847598
  • 44% vs 21.9% 150 mg · wk 16 · n 25 · Phase 2 · secondary NCT02847598
  • 48% vs 12.1% 150 mg · wk 12 · n 25 · Phase 2 · secondary NCT02847598
  • 38.5% vs 21.9% 50 mg · wk 16 · n 26 · Phase 2 · secondary NCT02847598
  • 38.5% vs 12.1% 50 mg · wk 12 · n 26 · Phase 2 · secondary NCT02847598
  • 16.7% vs 42.1% 150 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598
  • 50% vs 42.1% 50 mg · wk 24 · n 6 · Phase 2 · secondary NCT02847598

Steroid sparing

BCD-256
—Not reported
Litifilimab
—Trial running · NCT04961567
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCD-256: no structured comparison results are available for Systemic Lupus Erythematosus.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BCD-256: 0 of 4 rows · Litifilimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLitifilimab
Dropout rate
6.3%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 5 more results
8.3%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
8%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
11.5%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
Discontinued due to AEs
0%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 5 more results
2.1%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
Serious AEs
4.7%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 5 more results
6.3%450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
16.7%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
12%150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
0%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
3.8%50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
Most frequent reported AEs
450 mg
fall 6.3% (placebo 1.8%)
urinary tract infection 6.3% (placebo 7.1%)
diarrhoea 4.7% (placebo 5.4%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 5 more results
450 mg
injection site erythema 8.3% (placebo 0%)
arthralgia 6.3% (placebo 3.6%)
hypertension 6.3% (placebo 0%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
150 mg
influenza 33.3% (placebo 3.6%)
anaemia 16.7% (placebo 0%)
arthralgia 16.7% (placebo 3.6%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
150 mg
nasopharyngitis 20% (placebo 3.6%)
pruritus 12% (placebo 3.6%)
arthralgia 8% (placebo 3.6%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
50 mg
cystitis 16.7% (placebo 3.6%)
diarrhoea 16.7% (placebo 5.4%)
headache 16.7% (placebo 14.3%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
50 mg
headache 23.1% (placebo 14.3%)
back pain 11.5% (placebo 0%)
injection site erythema 11.5% (placebo 0%)
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Litifilimab

Active Joint Count -14.5 vs -12.7 placebo joints @ 24wk450 mg
absolute change · joints
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 2 more results
-13 vs -12.7 placebo joints @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-9 vs -12.7 placebo joints @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
CLASI-A -41.66% (n=42) vs -15.03% (n=31) placebo @ 16wk450 mg
percent change · % of baseline
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 14 more results
-44.36% (n=39) vs -36.63% (n=38) placebo @ 12wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-50.2% (n=39) vs -42.55% (n=38) placebo @ 16wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-60.59% (n=39) vs -45.4% (n=38) placebo @ 24wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-35.25% (n=44) vs -10.73% (n=32) placebo @ 12wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-47.11% (n=24) vs -15.03% (n=31) placebo @ 16wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-8.39% (n=6) vs -36.63% (n=38) placebo @ 12wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-6.19% (n=6) vs -42.55% (n=38) placebo @ 16wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-17.92% (n=6) vs -45.4% (n=38) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-47.82% (n=24) vs -10.73% (n=32) placebo @ 12wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-35.52% (n=23) vs -15.03% (n=31) placebo @ 16wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-29.32% (n=6) vs -36.63% (n=38) placebo @ 12wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-41.76% (n=6) vs -42.55% (n=38) placebo @ 16wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-58.61% (n=6) vs -45.4% (n=38) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-38.72% (n=23) vs -10.73% (n=32) placebo @ 12wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
CLASI-50 64.1% (n=39) vs 42.11% (n=38) placebo @ 24wk450 mg
responder rate · % of participants
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 8 more results
37.5% (n=48) vs 12.12% (n=33) placebo @ 12wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
46.51% (n=48) vs 21.88% (n=33) placebo @ 16wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
16.67% (n=6) vs 42.11% (n=38) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
48% (n=25) vs 12.12% (n=33) placebo @ 12wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
44% (n=25) vs 21.88% (n=33) placebo @ 16wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
50% (n=6) vs 42.11% (n=38) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
38.46% (n=26) vs 12.12% (n=33) placebo @ 12wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
38.46% (n=26) vs 21.88% (n=33) placebo @ 16wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
CLASI-A 4pt 71.79% (n=39) vs 57.89% (n=38) placebo @ 24wk450 mg
responder rate · % of participants
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 8 more results
47.92% (n=48) vs 33.33% (n=33) placebo @ 12wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
55.81% (n=48) vs 37.5% (n=33) placebo @ 16wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
16.67% (n=6) vs 57.89% (n=38) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
76% (n=25) vs 33.33% (n=33) placebo @ 12wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
72% (n=25) vs 37.5% (n=33) placebo @ 16wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
83.66% (n=6) vs 57.89% (n=38) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
50% (n=26) vs 33.33% (n=33) placebo @ 12wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
46.15% (n=26) vs 37.5% (n=33) placebo @ 16wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
CLASI-A 7pt 56.41% (n=39) vs 34.21% (n=38) placebo @ 24wk450 mg
responder rate · % of participants
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 8 more results
33.33% (n=48) vs 18.18% (n=33) placebo @ 12wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
41.86% (n=48) vs 21.88% (n=33) placebo @ 16wk450 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
16.67% (n=6) vs 34.21% (n=38) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
40% (n=25) vs 18.18% (n=33) placebo @ 12wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
48% (n=25) vs 21.88% (n=33) placebo @ 16wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
66.67% (n=6) vs 34.21% (n=38) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
38.46% (n=26) vs 18.18% (n=33) placebo @ 12wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
30.77% (n=26) vs 21.88% (n=33) placebo @ 16wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
SRI-4 56.25% (n=64) vs 28.57% (n=56) placebo @ 24wk450 mg
responder rate · % of participants
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 2 more results
16.67% (n=6) vs 28.57% (n=56) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
33.33% (n=6) vs 28.57% (n=56) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
SLEDAI-2K -4.4 vs -2.1 placebo score @ 24wk450 mg
absolute change · score
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 2 more results
-1.3 vs -2.1 placebo score @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-3 vs -2.1 placebo score @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
no New Organ System Affected 85.94% (n=64) vs 82.14% (n=56) placebo @ 24wk450 mg
responder rate · % of participants
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 2 more results
50% (n=6) vs 82.14% (n=56) placebo @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
100% (n=6) vs 82.14% (n=56) placebo @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
PGA VAS -2.45 vs -2.46 placebo score @ 24wk450 mg
absolute change · score
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
show 2 more results
-0.12 vs -2.46 placebo score @ 24wk150 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2
-2.05 vs -2.46 placebo score @ 24wk50 mg
NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-256's landscape · Litifilimab's landscape